Cord blood markers and newborn health study
Treatments studied
Part of Genetic & congenital, Women’s health & pregnancy clinical trials.
This study looks at two substances in the blood from the umbilical cord (IL-6 and lactate) to see if they can help doctors understand how well a newborn is doing after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are pregnant with one baby who is head-down.
- You are at least 37 weeks pregnant and in labor.
- You are willing to let the study team collect a blood sample from the umbilical cord after birth.
- You can provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for biological markers in the mother's blood that might predict how exposure to inflammation during pregnancy could change a baby's brain development. The goal is to understand these effects in healthy pregnancies and those with certain inflammatory conditions.
This study tracks pregnancies affected by hemolytic disease of the fetus and newborn (HDFN). It collects information to better understand the condition and improve care. You may join if you are pregnant with a history of a prior affected pregnancy and have a current antibody that could harm your baby.
This study tests a simple non-invasive score that uses blood flow in muscles to predict if a newborn has or will develop high inflammation levels (C-reactive protein). It may help doctors start treatment earlier in babies with breathing problems.
This study measures a protein (S100B) in cord blood from babies who had or did not need a blood transfusion in the womb for hemolytic disease. It looks for possible markers of brain health.
This study looks at how immune-related “NETs” might protect or possibly harm newborn babies during early inflammation or infection. It may help doctors understand which immune responses are helpful versus risky in the NICU.
This study measures a protein called S100B in umbilical cord blood to learn more about brain development in newborns with fetal growth restriction (FGR), a condition where a baby is smaller than expected. Understanding this protein could help doctors identify babies who may need extra support after birth.
Hear when a new Chorioamnionitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.